Most children tolerated oral immunotherapy, but peanut protein must be consumed daily and the effect on long-term tolerance is unknown.
Peanut allergy affects roughly 1% of children in developed countries and is the leading cause of food-allergy related deaths. Currently, avoidance is the only acceptable treatment and only 20% of patients outgrow their allergy. In a randomized, double-blind, crossover trial, researchers in the U.K. compared the efficacy of 26 weeks of escalating doses of peanut flour or usual care (peanut avoidance) in 99 children (age range, 7–16 years) with peanut allergy. Peanut protein doses were increased every 2 weeks in the clinic until patients tolerated 800 mg daily (roughly 5 peanuts).
After the first phase of the trial, 84% of patients in the active-treatment group tolerated the target dose and 62% tolerated a 1400 mg peanut challenge (desensitiza…
Reviewing Author
DisclosuresSpeaker’s BureauAstraZeneca; Incyte
DisclosuresSpeaker’s BureauAstraZeneca; Incyte